Search Results - "Laboure, Gaelle"
-
1
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
Published in Blood advances (10-04-2018)“…Outcomes for follicular lymphoma (FL) have greatly improved, but most patients will ultimately relapse. High total metabolic tumor volume (TMTV), computed from…”
Get full text
Journal Article -
2
Convalescent plasma transfusion for immunocompromised viremic patients with COVID‐19: A retrospective multicenter study
Published in Journal of medical virology (01-04-2024)“…This study aims to assess the safety, virological, and clinical outcomes of convalescent plasma transfusion (CPT) in immunocompromised patients hospitalized…”
Get full text
Journal Article -
3
Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group
Published in Blood (15-11-2022)Get full text
Journal Article -
4
High Incidence of HHV-6 Infection Associated with Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) Conditioning Regimen: Results of a Monocentric and Retrospective Study
Published in Blood (02-12-2016)“…Background: Because of the disruption of BCNU (Carmustine) in France during several months, and based on the results reported by Visani and colleagues (Visani…”
Get full text
Journal Article -
5
Number of Circulating t(14;18) Tumor Cells at Diagnosis Is Related to, but Add to the Prognostic Value of Metabolic Tumor Burden in Follicular Lymphoma
Published in Blood (03-12-2015)“…Beside the rare true leukemic forms of follicular lymphoma (FL), low levels of circulating tumor cells (CTC) are detected by PCR in the vast majority of FL…”
Get full text
Journal Article -
6
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort
Published in BMC public health (02-03-2021)“…Age-adjusted lymphoma incidence rates continue to rise in France since the early 80's, although rates have slowed since 2010 and vary across subtypes. Recent…”
Get full text
Journal Article -
7
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
Published in Blood advances (23-01-2024)“…•The REALYSA cohort is a source of real-world data of high quality for lymphoma thanks to a multi-step rigorous data validation process.•Effectiveness results…”
Get full text
Journal Article -
8
Potent Graft-Versus-Leukemia Effect After Reduced Intensity (RIC) Allogeneic Stem-Cell Transplantation (ASCT) As Post-Remission Therapy for Intermediate-Risk De-Novo Acute Myeloid Leukemia (AML) with FLT3-ITD Genotype or Wild-Type (WT) NPM1 and CEBPA without FLT3-ITD
Published in Blood (18-11-2011)“…Abstract 4129 In patients with cytogenetically normal AML, the mutational status of FLT3, NPM1 and CEBPA are associated with the outcome (Schlenk, NEJM 2008)…”
Get full text
Journal Article -
9
-
10
Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams -075
Published in Blood (03-12-2015)“…Background: The prognostic value of COO classification by immunohistochemistry (IHC) for de novo untreated advanced DLBCL remains controversial after…”
Get full text
Journal Article -
11
-
12
Fonctions télomériques et extra-télomériques de la télomérase dans les lymphomes T cutanés primitifs
Published in Morphologie (01-12-2015)“…Dans 70 à 90 % des cellules tumorales humaines, une activité télomérase est détectée alors que dans les tissus avoisinants non tumoraux, l’activité de la…”
Get full text
Journal Article -
13
Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3- ITD or Wild-Type NPM1 and CEBPA without FLT3- ITD
Published in Biology of blood and marrow transplantation (01-12-2012)“…To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT) as postremission therapy in adult intermediate-risk patients with…”
Get full text
Journal Article